Cholinesterase Inhibitors: Actions and Uses

Slides:



Advertisements
Similar presentations
Applying the Nursing Process to Drug Therapy
Advertisements

Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 11 Antiviral Drugs.
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Introduction to Clinical Pharmacology Chapter 33- Diuretics
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 04- The Nursing Process.
Drug Utilization Review (DUR)
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs.
Mosby items and derived items © 2005 by Mosby, Inc. Chapter 43 Nutrition.
Cognitive Enhancers. Dementia A syndrome due to disease of the brain, characterised by progressive, global deterioration in intellect including: Memory.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 6 Nonopiod (Nonnarcotic) Analgesics.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 18 Nonopioid Analgesics: Nonsteroidal Anti-Inflammatory Drugs.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 25 Central Nervous System Stimulants.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 7 Penicillins.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 15 Antifungal Drugs.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 9 Tetracyclines, Macrolides, and Lincosamides.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 17 Nonopioid Analgesics: Salicylates and Nonsalicylates.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 2 Application of Pharmacology in Nursing Practice.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 16 Antiparasitic Drugs.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 8 Cephalosporins.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 22 Antianxiety Drugs.
Alzheimer's: An Investigation into Treatment Options Dana McGuire and Jessica Scharfenberg MPH 543: Leadership and Organizational Management Concordia.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 24 Antidepressant Drugs.
Drugs Used for Diuresis Chapter 29 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
 The ARBs include the following drugs:  azilsartan (Edarbi),candesartan (Atacand), eprosartan (Teveten), irbesartan(Avapro), losartan (Cozaar), olmesartan.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 23 Sedatives and Hypnotics.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 10 Fluoroquinolones and Aminoglycosides.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 11 Miscellaneous Anti-Infectives.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 31 Anticonvulsants.
An unpleasant sensory or emotional experience associated with actual or potential tissue damage The World Health Organization (WHO) has stated that pain.
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 07- Penicillins.
Factors Affecting Drug Activity
Medications for Dementia
Antiprotozoal Agents Chapter 12. Antiprotozoal Agents Chapter 12.
Hormone Secretion The thyroid gland secretes the hormones thyroxine (T4) and tri-iodothyronine (T3), which help to control metabolism. This process is.
Antineoplastic Medications
What is Dementia? A term that describes a wide range of symptoms associated with a decline in memory or other thinking skills. Dementia may be severe.
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
Figure 19.1 Alzheimer disease and the resulting dementia occur when changes in the brain hamper neurotransmission.
Nursing Process in Pharmacology
Introduction to Clinical Pharmacology Chapter 20 Antianxiety Drugs
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
CNS Stimulants: Action #1
Alpha-Adrenergic Blocking Drugs: Actions and Uses
Introduction to Clinical Pharmacology Chapter 13 Nonopioid Analgesics: Salicylates and Nonsalicylates.
Posterior pituitary hormones: Vasopressin
Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs
Introduction to Sulfonamides
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Chapter 33 Acute Care.
Assessment of the Gastrointestinal System
Introduction to Clinical Pharmacology Chapter 11 Antiviral Drugs
Introduction to Clinical Pharmacology Chapter 42 Antidiabetic Drugs
Introduction to Clinical Pharmacology Chapter 13 Nonopioid Analgesics: Salicylates and Nonsalicylates.
Introduction to Clinical Pharmacology Chapter 33 Diuretics
Introduction to Clinical Pharmacology Chapter 48 Urinary Tract Anti-Infectives and Other Urinary Drugs.
Introduction to Clinical Pharmacology Chapter 4 The Nursing Process
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Introduction to Clinical Pharmacology Chapter 11 Antiviral Drugs
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
Cholinesterase Inhibitors: Actions and Uses
CNS Stimulants: Action #1
Introduction to Sedatives and Hypnotics #1
Cholinergic Blocking Drugs: Actions
Introduction to Clinical Pharmacology Chapter 26 Cholinergic Drugs
Find The Complete Information About – TTarceva Cost EErlotinib Tablets EErlotinib Price EErlotinib 150 Mg EErlotinib Side Effects TTarceva.
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Presentation transcript:

Introductory Clinical Pharmacology Chapter 33 Cholinesterase Inhibitors

Cholinesterase Inhibitors: Actions and Uses Cholinesterase inhibitors act to increase level of acetylcholine in CNS by inhibiting its breakdown and slowing neural destruction Uses Cholinesterase inhibitors are used to treat dementia associated with AD

Cholinesterase Inhibitors: Adverse Reactions Generalized adverse reactions Anorexia; nausea; vomiting; diarrhea; dizziness; headache Tacrine is particularly damaging to liver and can result in hepatotoxicity

Cholinesterase Inhibitors: Contraindications and Precautions Cholinesterase inhibitors are contraindicated in patients with hypersensitivity to drugs and during pregnancy and lactation Tacrine should not be used in patients with known liver dysfunction These drugs are used cautiously in patients with renal or hepatic disease; bladder obstruction; seizure disorders; sick sinus syndrome; gastrointestinal bleeding; asthma

Interactions Interactant Drug Effect of Interaction Anticholinergics Decreased effectiveness of anticholinergics Nonsteroidal anti-inflammatory drugs (NSAIDs) Increased risk of GI bleeding Theophylline Increased risk of theophylline toxicity

Nursing Process: Assessment Preadministration assessment The patient’s cognitive and functional ability are assessed before and during therapy Patients are assessed regarding orientation, calculation, recall, and language Assess the patient for agitation and impulsive behavior Obtain complete medical history and history of symptoms of AD from patient, family member, or patient’s hospital records

Nursing Process: Assessment Preadministration assessment (cont’d) Observe patient for what appears to be deviations from normal behavior pattern The nurse asks the family about unusual behaviors, such as wandering or outbursts of angry or frustrated behavior Assess patient’s vital signs and weight

Nursing Process: Assessment Ongoing assessment Includes both mental and physical assessment Initial assessments will be compared with ongoing assessments to monitor patient’s improvement after taking cholinesterase inhibitors

Nursing Process: Planning Expected outcomes include: Optimal response to drug therapy Support of patient needs related to management of adverse reactions Absence of injury Compliance with the prescribed therapeutic regimen

Nursing Process: Implementation Promoting an optimal response to therapy Develops care plan to meet patient’s individual needs Monitor for liver damage in patients taking tacrine, from at least week 4 to week 16 after initiation of therapy, after week 16 transaminase levels are monitored every 3 months

Nursing Process: Implementation Monitoring and managing patient needs Imbalanced nutrition: Less than body requirements Attention to dosing of medications can be helpful to decrease adverse GI reactions and promote nutrition Remove oral dosing syringe provided in protective container when rivastigmine is administered as oral solution

Nursing Process: Implementation Monitoring and managing patient needs (cont’d) Tacrine (Cognex) is administered orally 3 or 4 times a day, preferably on an empty stomach, 1 hour before or 2 hours after meals Patient should be offered a well-balanced diet with foods that are easy to chew and digest Fluid intake of 6 to 8 glasses of water daily is encouraged to prevent dehydration

Nursing Process: Implementation Monitoring and managing patient needs (cont’d) In later stage, patient may be fed through feeding syringe, or the caregiver can encourage chewing action by pressing gently on bottom of the patient’s chin and on the lips

Nursing Process: Implementation Monitoring and managing patient needs (cont’d) Risk for injury Physical decline and adverse reactions of dizziness and syncope place patient at risk for injury Use of side rails; keep the bed in low position; use night lights; frequent monitoring by nurse or caregiver will reduce risk of injury

Nursing Process: Implementation Educating the patient and family Explain any adverse reactions that may occur with specific drug and encourage caregiver or family members to contact primary health care provider immediately if serious drug reaction occurs Evaluate patient’s ability to assume responsibility for taking drugs at home

Nursing Process: Implementation Educating the patient and family (cont’d) Focus on educating family and major caregiver of patient needs Discuss drug regimen with patient, family member, and/or caregiver

Nursing Process: Evaluation Therapeutic effect is achieved Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions No injury is evident Patient, family member, or caregiver demonstrates understanding of the drug regimen

End of Presentation